Please login to the form below

Not currently logged in
Email:
Password:

MPDL3280A

This page shows the latest MPDL3280A news and features for those working in and with pharma, biotech and healthcare.

Roche gets first approval for PD-L1 inhibitor Tecentriq

Roche gets first approval for PD-L1 inhibitor Tecentriq

Specifically, the FDA has approved atezolizumab (MPDL3280A) - which will be sold as Tecentriq - for people with locally advanced or metastatic urothelial carcinoma (mUC) whose disease has progressed during or after

Latest news

More from news
Approximately 3 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Pharma deals during September 2013 Pharma deals during September 2013

    Roche sees the potential to combine these therapies with other immunotherapies already in its oncology portfolio, such as MPDL3280A, which targets the PD-L1 receptor on cancer cells.  .

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Webinar: Usability and UX: You’ve been asked to test...What next?
Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST...
Event: EphMRA Annual Conference
We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland....
Research Partnership and Janssen awarded runner-up in MR Excellence Awards
...

Infographics